The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andreas Argyrides - Wedbush Securities Inc., Research Division - Analyst
: Definitely, congrats on these very exciting results. So for Dr. Anzueto, how are you thinking about exacerbations versus symptoms, quality of life
measures in terms of prioritizing one over the other? And then I have one follow-up.
Antonio Anzueto
Sure. Yes, so I think there's a couple of important issues here. I think it's important to emphasize that this is a medication who has both
anti-inflammatory and bronchodilator effects. So we see the bronchodilator effect in the other phosphodiesterase that we cannot see even with
the oral medication. So there -- it's an bronchodilator and works very well. I mean there is -- the data is very strong. I think what it makes more
interesting is the significant reduction in the exacerbation. The impact in exacerbation having 42% decrease of the rate of exacerbation and a
similar 42% decrease of the time to the first exacerbation, I think this is really striking.
Certainly, the -- so how we translate that into a quality of life? I mean the quality of life if you look at the Slide #10, when patients will receive -- for
example, at 6 weeks, there is a very striking difference between the intervention group versus the placebo. This effect kind of gets lots over time.
I think there are several issues. Some of the issues are were losing some individuals, the people who stay are more [feeded]. And as also, and it was
mentioned before, we have to understand the impact of the pandemia and this at 24 weeks. So having the second Phase III trial that's going to be
a longer than ENHNACE-1, so we're going to be able to better understand the impact in quality of life. But the fact that we've seen this significant
decrease in exacerbation at 24 weeks, I think is very remarkable.
Question: Andreas Argyrides - Wedbush Securities Inc., Research Division - Analyst
: Okay, fantastic. And then just I have one follow-up for Dr. Anzueto. When you -- now with this exacerbation data in hand, where do you see
ensifentrine sitting in the treatment paradigm? How would you look to prescribe it?
Antonio Anzueto
Sure. So this is on top of patients being already in long-acting bronchodilators. So one, this is a nebulized medication. And today, we have 4 other
-- 3 other classes of medication given nebulization. So nebulization is pretty much becoming the standard of care, ask many patients. And I can
see this given to patients that either having persistent exacerbation despite being on maximum therapy, are also being used in patients who have
bronchodilators having this medication to prevent future exacerbations. This will be a medication that, with this data, improvement in lung function
and reduction in exacerbation. The medication will give patients who are risk for these events.
|
